» Articles » PMID: 23533749

Effects of ROI Placement on PET-Based Assessment of Tumor Response to Therapy

Overview
Date 2013 Mar 28
PMID 23533749
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose. Quantitative PET response assessment during therapy requires regions of interest (ROI). Commonly, a fixed-size ROI is placed at the maximum uptake point in the pretreatment study. For intratreatment, the ROI is placed either at the maximum uptake point (ROIpeak) or at the same location as the pretreatment ROI (ROIsame). We have evaluated the effects of the ROI placement on response assessment. Methods. PET scans of 15 head and neck cancer patients were used to evaluate the effects of the two ROI methods on response assessment. Results. The average intratreatment ROIpeak uptake was 13.4% higher than the ROIsame uptake (range -14% to 38%). The average relative change in ROIpeak uptake was 7.9% lower than ROIsame uptake (range -5% to 36%), resulting in ambiguous tumour classification in 19% of the tumours. Conclusion. Quantitative PET response assessment using a fixed-size ROI is sensitive the ROI placement. The difference between ROIpeak and ROIsame could be substantial resulting in ambiguous response assessment. Although the fixed-size ROI is simple to implement, it is also prone to the limitations and should be used with caution. Clinical trial data are necessary to establish reliable thresholds for fixed-size ROI techniques and to evaluate their efficacy for response assessment.

Citing Articles

Deep learning for automatic organ and tumor segmentation in nanomedicine pharmacokinetics.

Dhaliwal A, Ma J, Zheng M, Lyu Q, Rajora M, Ma S Theranostics. 2024; 14(3):973-987.

PMID: 38250039 PMC: 10797295. DOI: 10.7150/thno.90246.


Hybrid PET/MR Kernelised Expectation Maximisation Reconstruction for Improved Image-Derived Estimation of the Input Function from the Aorta of Rabbits.

Deidda D, Karakatsanis N, Robson P, Calcagno C, Senders M, Mulder W Contrast Media Mol Imaging. 2019; 2019:3438093.

PMID: 30800014 PMC: 6360049. DOI: 10.1155/2019/3438093.


Radiologic-pathologic analysis of quantitative 3D tumour enhancement on contrast-enhanced MR imaging: a study of ROI placement.

Chockalingam A, Duran R, Sohn J, Schernthaner R, Chapiro J, Lee H Eur Radiol. 2015; 26(1):103-13.

PMID: 25994198 PMC: 4654989. DOI: 10.1007/s00330-015-3812-2.

References
1.
Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L . Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2006; 24(34):5366-72. DOI: 10.1200/JCO.2006.05.7406. View

2.
Barker Jr J, Garden A, Ang K, ODaniel J, Wang H, Court L . Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system. Int J Radiat Oncol Biol Phys. 2004; 59(4):960-70. DOI: 10.1016/j.ijrobp.2003.12.024. View

3.
Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma A . Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 2000; 35(13):1773-82. DOI: 10.1016/s0959-8049(99)00229-4. View

4.
Ott K, Fink U, Becker K, Stahl A, Dittler H, Busch R . Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol. 2003; 21(24):4604-10. DOI: 10.1200/JCO.2003.06.574. View

5.
Vanderhoek M, Perlman S, Jeraj R . Impact of the definition of peak standardized uptake value on quantification of treatment response. J Nucl Med. 2012; 53(1):4-11. PMC: 3308343. DOI: 10.2967/jnumed.111.093443. View